Clinical trial
Randomized, Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Subcutaneous Beloranib in Suspension) in Obese Subjects With Prader-Willi Syndrome to Evaluate Total Body Weight, Food-related Behavior, and Safety Over 6 Months
NCT02179151 is registered in ClinicalTrials.gov with Zafgen, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized, Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Subcutaneous Beloranib in Suspension) in Obese Subjects With Prader-Willi Syndrome to Evaluate Total Body Weight, Food-related Behavior, and Safety Over 6 Months
- Lead sponsor
- Zafgen, Inc.
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- September 30, 2014
- Completion date
- October 31, 2016
- Enrollment
- 108 (actual)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.